Comparing the Cost of Every GLP-1 Medication in 2026
A detailed breakdown of what you will actually pay for GLP-1 medications in 2026, including insurance coverage, manufacturer discounts, and compounding options.
The Price Landscape for GLP-1 Medications
Understanding what you will actually pay for GLP-1 medications in 2026 is more complicated than looking at a single price tag. The cost depends on your insurance coverage, the specific medication prescribed, your pharmacy choice, and whether you qualify for manufacturer discount programs. We have compiled the most comprehensive pricing analysis available to help you navigate these variables.
The sticker prices for brand-name GLP-1 medications remain high, with monthly costs ranging from $900 to over $1,500 without insurance. However, the actual out-of-pocket expense for most patients is significantly lower thanks to insurance coverage, copay assistance programs, and the growing availability of compounded alternatives.
Brand-Name Medication Pricing
Semaglutide Products
Ozempic (for diabetes): The list price remains approximately $935 per month for a standard dose. Most commercial insurance plans cover Ozempic for type 2 diabetes with copays ranging from $25 to $150 per month. Medicare Part D coverage varies by plan but has improved in 2026 following policy changes.
Wegovy (for weight loss): List price sits around $1,349 per month. Insurance coverage for Wegovy has expanded significantly in 2026, with an estimated 45% of commercial plans now covering it for weight management. However, many plans impose strict BMI requirements and may require documentation of failed prior weight loss attempts.
Tirzepatide Products
Mounjaro (for diabetes): Priced at approximately $1,023 per month, Mounjaro has gained significant market share due to its dual GIP/GLP-1 mechanism. Insurance coverage for diabetic indications is broadly available, with typical copays of $25-$100.
Zepbound (for weight loss): Launched at $1,059 per month, Zepbound has quickly become a popular choice. Eli Lilly has been aggressive with its copay savings programs, offering eligible patients their first fills at significantly reduced prices.
Compounded Alternatives
The compounding market for GLP-1 medications has grown rapidly, offering monthly costs between $150 and $500 depending on the medication and dosage. Compounded semaglutide and tirzepatide are available from 503A (individual prescription) and 503B (outsourcing facility) pharmacies.
It is critical to understand the difference between these pharmacy types. 503B outsourcing facilities face more rigorous FDA oversight and testing requirements, while 503A pharmacies operate under state-level regulation. The quality difference can be significant. For detailed information about verifying compounding pharmacy credentials, GLP-1 Watchdog maintains an updated guide.
Important: The FDA has challenged the shortage status of some GLP-1 medications, which could affect the legality of compounding certain formulations. Check current regulations before purchasing compounded versions.
Insurance Coverage Breakdown
Insurance coverage for GLP-1 medications has evolved significantly. Here is what to expect from different payer types in 2026:
- Employer-sponsored commercial plans: Coverage rates have climbed to approximately 55% for weight loss indications, up from 35% in 2024. Large employers are increasingly recognizing the long-term cost savings of weight management medications.
- Individual marketplace plans: Coverage remains spotty, with roughly 30% of silver-tier and above plans including GLP-1 coverage for obesity. Always check the formulary before enrolling.
- Medicare Part D: Coverage for diabetes indications is standard. Weight loss coverage has begun rolling out under certain Medicare Advantage plans but remains limited in traditional Medicare.
- Medicaid: Coverage varies dramatically by state. As of early 2026, approximately 20 states provide some form of Medicaid coverage for GLP-1 weight loss medications.
Manufacturer Savings Programs
Both Novo Nordisk and Eli Lilly maintain patient assistance programs that can dramatically reduce costs:
Novo Nordisk Patient Assistance: Eligible uninsured patients may qualify for free medication. Commercially insured patients can use the Wegovy savings card to reduce copays to as low as $0 for up to 13 fills.
Lilly Savings Card: Commercially insured patients can pay as little as $25 per month for Mounjaro or Zepbound for up to 24 months. The program excludes patients on government insurance.
Hidden Costs to Consider
Beyond the medication itself, factor in these additional expenses:
- Doctor visits: Initial consultations ($150-$400) and ongoing monitoring ($75-$200 per visit) add up, especially with telehealth programs that charge per appointment.
- Lab work: Metabolic panels, A1C tests, and liver function tests are typically recommended quarterly. Expect $50-$300 per round depending on insurance.
- Supplies: Alcohol swabs, sharps containers, and needle tips for some pen types add roughly $10-$20 per month.
- Nutritional support: Many programs charge separately for dietitian consultations and meal planning services.
How to Minimize Your Costs
Based on our research, here are the most effective strategies for reducing GLP-1 medication expenses:
- Always check manufacturer copay cards before filling your prescription. These programs are updated frequently and can save hundreds per month.
- Compare prices across pharmacies. Retail, mail-order, and specialty pharmacies can charge vastly different amounts for the same medication.
- Ask your doctor about therapeutic alternatives. If one GLP-1 is not covered by your insurance, another may be on the preferred formulary.
- If considering compounded medications, research the pharmacy thoroughly. Verify their accreditation and review their testing protocols.
- Appeal insurance denials. Many initial denials for weight loss indications are overturned on appeal with proper documentation from your physician.
Looking Ahead
The pricing landscape for GLP-1 medications is expected to shift further in the coming years as biosimilar versions approach the market and competition increases. Several generic semaglutide products are in development, which should drive costs down significantly by 2028-2029. In the meantime, patients should use every available resource to manage costs while accessing these effective medications.
About This Review
This article was researched and written by the Health Products In Review editorial team. We maintain strict editorial independence and do not accept payment from companies whose products we review. Last updated: March 25, 2026.